Partnering for Scale: Maximizing Allogeneic Cell Therapy Success using the Right CDMO
- Speed to Clinic & Regulatory De-risking: How leveraging a mature CDMO platform and established CMC frameworks compresses timelines for first-in-human readiness.
- Scalability by Design: Overcoming allogeneic bottlenecks (donor management, upstream/downstream optimization, and analytical readiness) to secure future global clinical supply.
- Building the Right Operating Model: Navigating build vs. buy tradeoffs and risk-sharing structures – informed by real-world allogeneic program lessons.